Literature DB >> 2360592

Flow cytometric evaluation of epithelial ovarian cancer.

V M Barnabei1, D S Miller, K D Bauer, T M Murad, A W Rademaker, J R Lurain.   

Abstract

We investigated the prognostic significance of deoxyribonucleic acid content and proliferative activity of tumor cell populations as measured by flow cytometry of the tumor specimens from 115 women with epithelial ovarian cancer. Deoxyribonucleic acid aneuploidy was found in 87 of 115 (76%) of these cancers with a mean deoxyribonucleic acid index of 1.6 and S-phase fraction of 14.7%. The S-phase fraction of the 28 (24%) diploid tumors was 7.0%. Deoxyribonucleic acid ploidy was significantly correlated with survival. S-phase fraction was significantly correlated with ploidy, residual tumor, histology, grade, ascites, time to recurrence, and survival. Diploidy versus aneuploidy were the best discriminating values for deoxyribonucleic acid index and an S-phase fraction of greater or less than 18% for that parameter. Multivariate analysis revealed stage, S-phase fraction, residual tumor, and grade to be independently associated with time to recurrence, and stage, age, S-phase fraction, and largest metastases were factors associated with survival. Deoxyribonucleic acid ploidy did not significantly improve either model. These results suggest that abnormalities of deoxyribonucleic acid content and the proliferative activity of tumor cell populations are reflective of their biologic activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2360592     DOI: 10.1016/0002-9378(90)90924-v

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

1.  Ras gene activation in malignant cells of human ovarian carcinoma peritoneal fluids.

Authors:  D N Dokianakis; M N Varras; M Papaefthimiou; J Apostolopoulou; H Simiakaki; E Diakomanolis; D A Spandidos
Journal:  Clin Exp Metastasis       Date:  1999-06       Impact factor: 5.150

2.  DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer.

Authors:  Alain G Zeimet; Heidi Fiegl; Georg Goebel; Francis Kopp; Claude Allasia; Daniel Reimer; Ilona Steppan; Elisabeth Mueller-Holzner; Melanie Ehrlich; Christian Marth
Journal:  Gynecol Oncol       Date:  2011-01-20       Impact factor: 5.482

3.  P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms.

Authors:  Nesrin Gursan; Sare Sipal; Muhammed Calik; Cemal Gundogdu
Journal:  Eurasian J Med       Date:  2009-04

4.  Multivariate analyses of DNA index, p62c-myc, and clinicopathological status of patients with ovarian cancer.

Authors:  M Curling; S Stenning; C N Hudson; J V Watson
Journal:  J Clin Pathol       Date:  1998-06       Impact factor: 3.411

5.  Plasmonic Nanoparticle-Based Digital Cytometry to Quantify MUC16 Binding on the Surface of Leukocytes in Ovarian Cancer.

Authors:  Sinyoung Jeong; Germán González; Alexander Ho; Nicholas Nowell; Lauren A Austin; Jawad Hoballah; Fatima Mubarak; Arvinder Kapur; Manish S Patankar; Daniel W Cramer; Petra Krauledat; W Peter Hansen; Conor L Evans
Journal:  ACS Sens       Date:  2020-09-10       Impact factor: 7.711

6.  Comparison of flow cytometric DNA content analysis in fresh and paraffin-embedded ovarian neoplasms: a prospective study.

Authors:  S Eissa; A Khalifa; M Laban; A Elian; W E Bolton
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

7.  DNA Cytometry and Nuclear Morphometry in Ovarian Benign, Borderline and Malignant Tumors.

Authors:  Amina A Gamal El Din; Manal A Badawi; Shereen E Abdel Aal; Nihad A Ibrahim; Fatma A Morsy; Nermeen M Shaffie
Journal:  Open Access Maced J Med Sci       Date:  2015-10-01

8.  Assessment of the diagnostic and prognostic relevance of ACAT1 and CE levels in plasma, peritoneal fluid and tumor tissue of epithelial ovarian cancer patients - a pilot study.

Authors:  Vijayalakshmi Ayyagari; Maio Li; Zvi Pasman; Xinjia Wang; Somaja Louis; Paula Diaz-Sylvester; Kathleen Groesch; Teresa Wilson; Laurent Brard
Journal:  BMC Cancer       Date:  2022-04-10       Impact factor: 4.430

9.  Proliferating cell nuclear antigen (PCNA) immunostaining--a prognostic factor in ovarian cancer?

Authors:  H Thomas; M M Nasim; C E Sarraf; M R Alison; S Love; H E Lambert; P Price
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.